5 completed, 1 terminated, 1 withdrawn. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Eosinophilic enteropathy: new trials by email Literature Review of Eosinophilic enteropathy trials Research Report on Eosinophilic enteropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis CC-93538, Placebo - Eosinophilic Gastroenteritis | Phase 3 | Completed | Celgene | 48 | 2022-03-04 | 2026-09-14 |
| Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) Benralizumab, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 3 | Terminated | AstraZeneca | 12 | 2022-01-18 | 2025-07-14 |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Duodenitis, Eosinophilic Gastroenteritis | Phase 3 | Completed | Allakos Inc. | 94 | 2021-05-20 | 2024-01-02 |
| An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) lirentelimab - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Completed | Allakos Inc. | 159 | 2020-12-03 | 2024-04-22 |
| A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) lirentelimab (AK002), Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Completed | Allakos Inc. | 181 | 2020-06-18 | 2024-01-02 |
| Benralizumab for Eosinophilic Gastritis (BEGS) Benralizumab, Placebo - Eosinophilic Gastritis or Gastroenteritis | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 26 | 2018-04-23 | 2022-02-03 |
Eosinophilic Esophagitis (3) · Gastroenteritis (3) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (1) · Stomach Diseases (1)
Digestive System Diseases (4) · Gastrointestinal Diseases (4) · Eosinophilia (3) · Esophageal Diseases (3) · Esophagitis (3) · Gastroenteritis (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Leukocyte Disorders (3)
AK002 (4) · benralizumab (2) · cendakimab (1)
Allakos Inc. (4) · AstraZeneca (1) · Celgene (1) · Children's Hospital Medical Center, Cincinnati (1)
United States (6) · Japan (2) · Brazil (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Ukraine (1) · Vietnam (1)
Craig Paterson, MD (3) · Craig Patterson, MD (1) · Marc E Rothenberg, MD, PhD (1) · Marc E. Rothenberg, MD, PhD (1)